Clinical Trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

MOA: Teclistamab targets the CD3 receptor complex on T cells and BCMA on B-lineage cells. Talquetamab targets the D3 receptor complex in T cells and GPRC5D expressing cells.

Key Eligibility Criteria:

• Must have documented diagnosis of MM according to the IMWG diagnostic criteria
• Must have received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody
• Patients with a high tumor burden, defined as having ≥60% plasma cell infiltrate on the bone marrow biopsy or aspirate, whichever is higher, or with multiple extramedullary disease sites or plasmacytomas are excluded
• Patients with a rapidly progressing disease per investigator assessment are excluded